Study to Compare the Immunogenicity and Safety of 3 Lots of NVX-CoV2373 in Adults
NCT ID: NCT05463068
Last Updated: 2023-07-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
911 participants
INTERVENTIONAL
2022-07-11
2022-09-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Strain Change Study for SARS-CoV-2 rS Vaccines
NCT06409663
Safety and Immunogenicity of NVX-CoV2705
NCT07079670
Phase 3 Boosting Study for the SARS-CoV-2 rS Variant Vaccines
NCT05372588
Phase 3 Study of Novavax Vaccine(s) as Booster Dose After mRNA Vaccines
NCT05875701
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2
NCT04611802
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Lot 1
1 intramuscular (IM) injection of NVX-CoV2373 of 0.5 mL injection volume on Day 1.
NVX-Cov2373
Intramuscular (deltoid) injection of SARS-CoV-2 rS co-formulated with Matrix-M adjuvant (0.5 mL) on Day 1
Lot 2
1 intramuscular (IM) injection of NVX-CoV2373 of 0.5 mL injection volume on Day 1.
NVX-Cov2373
Intramuscular (deltoid) injection of SARS-CoV-2 rS co-formulated with Matrix-M adjuvant (0.5 mL) on Day 1
Lot 3
1 intramuscular (IM) injection of NVX-CoV2373 of 0.5 mL injection volume on Day 1.
NVX-Cov2373
Intramuscular (deltoid) injection of SARS-CoV-2 rS co-formulated with Matrix-M adjuvant (0.5 mL) on Day 1
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
NVX-Cov2373
Intramuscular (deltoid) injection of SARS-CoV-2 rS co-formulated with Matrix-M adjuvant (0.5 mL) on Day 1
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Adults 18 to 49 years of age, inclusive, at screening
2. Willing and able to give informed consent prior to study enrollment and to comply with study procedures.
3. Participants of childbearing potential (defined as any participant who has experienced menarche and who is NOT surgically sterile \[ie, hysterectomy, bilateral tubal ligation, or bilateral oophorectomy\] or postmenopausal \[defined as amenorrhea at least 12 consecutive months\]) must agree to be heterosexually inactive from at least 28 days prior to enrollment and through the end of study (EOS) visit OR agree to consistently use a medically acceptable method of contraception from at least 28 days prior to enrollment and through the EOS visit.
4. Is medically stable, as determined by the investigator (based on review of health status, vital signs \[to include body temperature\], medical history, and targeted physical examination \[to include body weight\]). Vital signs must be within medically acceptable ranges prior to the study vaccination
5. Agree to not participate in any other SARS-CoV-2 prevention or treatment trials for the duration of the study.
Note: For participants who become hospitalized with coronavirus disease 2019 (COVID-19), participation in investigational treatment studies is permitted.
6. Documented receipt of either 2 or 3 doses of the investigational Novavax vaccine with Matrix-M adjuvant (NVX- CoV2373); OR documented receipt of a full course of an FDA-authorized/approved COVID-19 vaccine; OR documented receipt of a full course of heterologous COVID-19 vaccines mentioned above. The most recent dose must have been administered at least 6 months prior to study vaccination.
Exclusion Criteria
1. History of laboratory-confirmed (by polymerase chain reaction \[PCR\] or rapid antigen test)COVID-19 infection ≤ 4 months prior to randomization.
2. Current participation in research involving receipt of an investigational product (drug/biologic/device).
3. Any known allergies or history of anaphylaxis to the active substance or any of the other ingredients contained in the investigational product.
4. Any autoimmune or immunodeficiency disease/condition (iatrogenic or congenital) or therapy that causes clinically significant immunosuppression.
5. Received any vaccine ≤ 90 days prior to study vaccination, except for influenza vaccine which may be received 4 days prior to study vaccine, or rabies vaccine which may be received at any time if medically indicated.
6. Received immunoglobulin, blood-derived products, or immunosuppressant drugs within 90 days prior to study vaccination, except for rabies immunoglobulin which may be given if medically indicated.
7. Active cancer (malignancy) on chemotherapy that is judged to cause significant immunocompromise within 1 year prior to first study vaccination (with the exception of malignancy cured via excision, at the discretion of the investigator).
8. Participants who are breastfeeding, pregnant, or who plan to become pregnant prior to the EOS visit.
9. Suspected or known history of alcohol abuse or drug addiction within 3 months prior to the study vaccine dose that, in the opinion of the investigator, might interfere with protocol compliance.
10. Any other condition that, in the opinion of the investigator, would pose a health risk to the participant if enrolled or could interfere with evaluation of the trial vaccine or interpretation of study results (including neurologic or psychiatric conditions likely to impair the quality of safety reporting).
11. Study team member or immediate family member of any study team member (inclusive of Sponsor, clinical research organization \[CRO\], and study site personnel involved in the conduct or planning of the study).
12. Participants with a history of myocarditis or pericarditis.
18 Years
49 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novavax
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Development
Role: STUDY_DIRECTOR
Novavax, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Long Beach Clinical Trial Services Inc.
Long Beach, California, United States
Benchmark Research
Sacramento, California, United States
Accel Clinical Research
DeLand, Florida, United States
Research Centers of America
Hollywood, Florida, United States
Jacksonville Center for Clinical Research
Jacksonville, Florida, United States
Multi-Specialty Research Associates, Inc.
Lake City, Florida, United States
Cen/Excel ACMR
Atlanta, Georgia, United States
Meridian Clinical Research
Savannah, Georgia, United States
CRA Headlands
Stockbridge, Georgia, United States
Velocity Clinical Research
Boise, Idaho, United States
Meridian Clinical Research
Sioux City, Iowa, United States
Meridian Clinical Research
Baton Rouge, Louisiana, United States
MedPharmics
Gulfport, Mississippi, United States
Sundance Clinical Research
St Louis, Missouri, United States
Meridian Clinical Research
Norfolk, Nebraska, United States
Meridian Clinical Research
Omaha, Nebraska, United States
Meridian Clinical Research
Endwell, New York, United States
Rochester Clinical Research
Rochester, New York, United States
OnSite Clinical Solutions, LLC
Charlotte, North Carolina, United States
CTI Clinical Research Center
Cincinnati, Ohio, United States
Velocity Clinical Research
Cleveland, Ohio, United States
Lynn Health Science Institute
Oklahoma City, Oklahoma, United States
Tekton Research
Yukon, Oklahoma, United States
Velocity Clinical Research
Grants Pass, Oregon, United States
Velocity Clinical Research
East Greenwich, Rhode Island, United States
Benchmark Research
Austin, Texas, United States
Tekton Research
Austin, Texas, United States
Benchmark Research
Houston, Texas, United States
Research Your Health
Plano, Texas, United States
Tekton Research
San Antonio, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Raiser F, Davis M, Adelglass J, Cai MR, Chau G, Cloney-Clark S, Eickhoff M, Kalkeri R, McKnight I, Plested J, Zhu M, Dunkle LM; 2019nCoV-307 study team. Immunogenicity and safety of NVX-CoV2373 as a booster: A phase 3 randomized clinical trial in adults. Vaccine. 2023 Sep 22;41(41):5965-5973. doi: 10.1016/j.vaccine.2023.07.056. Epub 2023 Aug 30.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2019nCoV-307
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.